Identify your lead solid form early to reduce timelines and downstream costs

November 08, 2024

Remove from favorites

Add to favorites

This article, according to a webinar by Lonza Small Molecules, argues that prioritizing identification of the optimal solid form for a drug during the early phases of development can significantly reduce development time and costs. The author, Abhijeet S. Sinha, Manager of Solid Form Services (SFS) at Lonza, details the process of solid form screening, which includes looking at polymorphs, salts, and cocrystals. He also discusses risk assessments to nominate the most suitable crystalline form for further development. The article highlights that SFS can perform these screenings in early stages and offer additional assessments and troubleshooting for later phases.